News for hackers. Stuff that matters.

A comment on The business of extracting knowledge from academic publications. Parent comment

Re:The business of extracting knowledge from academic public... by petra on Thursday November 02, 2023 @02:15AM (#38109584)
For a good computational platform, that can pinpoint unique and valuable candidates , isn't there an option to do license/consult in exchange for royalties ?
[ Parent | on HN ]
Re:The business of extracting knowledge from academic public... by pfisherman on Thursday November 02, 2023 @09:52AM (#38113511)
No. Makes more sense to license the asset (molecule). And even then, big pharma companies won’t talk to you until your molecule is in phase 2.

If anybody with an AI pharma start up tells you they plan to make money by licensing their platform, then run the other way because it is a red flag.

If you want to see what a real “AI” pharma company looks like check out Vertex pharmaceuticals.

[ Parent | on HN ]